Categories: Health

HUTCHMED to Announce 2025 Final Results

 | Source: HUTCHMED (China) Limited

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).

Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
     Ben Atwell / Tim Stamper      +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith +44 20 7260 1000
GlobeNews Wire

Recent Posts

CoinW Partners with Luka Modri as Global Brand Ambassador

HONG KONG, April 9, 2026 /PRNewswire/ -- CoinW, a global cryptocurrency asset trading platform, is…

8 minutes ago

Sandmark Crypto Intelligence Report Shows Credible Insight Drives Investment Confidence

38% of finance professionals who personally hold crypto view it as a growth opportunity with strong…

8 minutes ago

Oceanus Group and HashKey Group Announce Strategic Partnership to Modernize Global Trade Finance via Stablecoin Settlement

SINGAPORE, April 9, 2026 /PRNewswire/ -- Oceanus Group Limited ("Oceanus"), an SGX-listed food security platform…

8 minutes ago

Duck Creek Launches Duck Creek Reinsurance with Active Delivery to Help Insurers Simplify Program Management and Improve Financial Control

The cloud-native solution delivers continuous updates, real-time visibility, and streamlined operations without system disruptionBOSTON, April 8, 2026 /PRNewswire/…

8 minutes ago

MEXC Appoints Vugar Usi as CEO to Drive Global ‘Infinite Opportunities’ Vision

After returning $1B to users through its 0-fee model, MEXC enters the world's Top 5…

8 minutes ago

Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model

A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated…

4 hours ago